Bristol Myers Squibb nabs iPierian in $175M buyout

Bristol-Myers Squibb now holds the power on a pipeline of neurodegenerative disease therapies after buying San Francisco-based IPierian for $175 million. iPierian is reportedly one of the first companies to work with stem cells to coax them into carrying out particular functions.

There is a rumor that Bristol-Myers may be up for spending another potential $550 million to continue iPierian's research and development, including treatments aimed at Alzheimer's. 

Trimed Popup
Trimed Popup